HMGA2 expression analysis in cytological and paraffin-embedded tissue specimens of thyroid tumors by relative quantitative RT-PCR

Diagnostic Molecular Pathology

Volumn 20, Issue 2, 2011, Pages 71-80

  Jin, Long ^a   Lloyd, Ricardo V ^a   Nassar, Aziza ^a   Lappinga, Paul J ^a   Sebo, Thomas J ^a   Swartz, Kathy ^a   Seys, Amber R ^a   Erickson Johnson, Michele R ^a   Roth, Christopher W ^a   Evers, Barbara R ^a   Oliveira, Andre M ^a   Zhang, Jun ^a  

^a MAYO CLINIC   (United States)

Author keywords

HMGA2; quantitative RT PCR; thyroid

Indexed keywords

HIGH MOBILITY GROUP A2 PROTEIN; MESSENGER RNA;

ANAPLASTIC CARCINOMA; ARTICLE; ASPIRATION BIOPSY; ASPIRATION CYTOLOGY; CANCER TISSUE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; GENE EXPRESSION; GENE EXPRESSION PROFILING; HASHIMOTO DISEASE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; NUCLEOTIDE SEQUENCE; ONCOCYTOMA; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RELIABILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; THYROID ADENOMA; THYROID FOLLICULAR CARCINOMA; THYROID NODULE; THYROID PAPILLARY CARCINOMA; THYROID TUMOR;

BIOPSY, FINE-NEEDLE; GENE EXPRESSION PROFILING; GENETIC MARKERS; HMGA2 PROTEIN; HUMANS; PATHOLOGY, MOLECULAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; THYROID NEOPLASMS; TISSUE FIXATION;

EID: 79958046619     PISSN: 10529551     EISSN: 15334066     Source Type: Journal    
DOI: 10.1097/PDM.0b013e3181ed784d     Document Type: Article

References (41)

1. Mangano JJ. Geographic variation in U.S. thyroid cancer incidence and a cluster near nuclear reactors in New Jersey, New York, and Pennsylvania. Int J Health Serv. 2009;39:643-661.
2. Hundahl SA, Fleming ID, Fremgen AM, et al. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer. 1998;83:2638-2648. (Pubitemid 29019586)
3. Lloyd RV, Erickson LA, Casey MB, et al. Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma. Am J Surg Pathol. 2004;28:1336-1340. (Pubitemid 39336372)
4. Tyler DS, Shaha AR, Udelsman RA, et al. Thyroid cancer: 1999 update. Ann Surg Oncol. 2000;7:376-398.
5. Gharib H, Goellner JR, Zinsmeister AR, et al. Fine-needle aspiration biopsy of the thyroid. The problem of suspicious cytological findings. Ann Intern Med. 1984;101:25-28. (Pubitemid 14088062)
6. Ashar HR, Fejzo MS, Tkachenko A, et al. Disruption of the architectural factor HMGI-C: DNA-binding AT hook motifs fused in lipomas to distinct transcriptional regulatory domains. Cell. 1995;82:57-65.
7. Schoenmakers EF, Wanschura S, Mols R, et al. 1995. Recurrent rearrangements in the high mobility group protein gene, HMGI-C, in benign mesenchymal tumours. Nat Genet. 1995;10:436-444.
8. Berlingieri MT, Pierantoni GM, Giancotti V, et al. Thyroid cell transformation requires the expression of the HMGA1 proteins. Oncogene. 2002;21:2971-2980. (Pubitemid 34522896)
9. Lovell-Badge R. Developmental genetics. Living with bad architecture. Nature. 1995;376:725-726.
10. Tessari MA, Gostissa M, Altamura S, et al. Transcriptional activation of the cyclin A gene by the architectural transcription factor HMGA2. Mol Cell Biol. 2003;23:9104-9116. (Pubitemid 37499800)
11. Zhou X, Benson KF, Ashar HR, et al. Mutation responsible for the mouse pygmy phenotype in the developmentally regulated factor HMGI-C. Nature. 1995;376:771-774.
12. Chiappetta G, Avantaggiato V, Visconti R, et al. High level expression of the HMGI (Y) gene during embryonic development. Oncogene. 1996;13:2439-2446. (Pubitemid 27026027)
13. Hirning-Folz U, Wilda M, Rippe V, et al. The expression pattern of the Hmgic gene during development. Genes Chromosomes Cancer. 1998;23:350-357. (Pubitemid 28507375)
14. Hristov AC, Cope L, Reyes MD, et al. HMGA2 protein expression correlates with lymph node metastasis and increased tumor grade in pancreatic ductal adenocarcinoma. Mod Pathol. 2009;22:43-49.
15. Abe N, Watanabe T, Suzuki Y, et al. An increased high-mobility group A2 expression level is associated with malignant phenotype in pancreatic exocrine tissue. Br J Cancer. 2003;89:2104-2109. (Pubitemid 38030910)
16. Sarhadi VK, Wikman H, Salmenkivi K, et al. Increased expression of high mobility group A proteins in lung cancer. J Pathol. 2006; 209:206-212. (Pubitemid 43805416)
17. Di Cello F, Hillion J, Hristov A, et al. HMGA2 participates in transformation in human lung cancer. Mol Cancer Res. 2008;6:743-750.
18. Meyer B, Loeschke S, Schultze A, et al. HMGA2 overexpression in non-small cell lung cancer. Mol Carcinog. 2007;46:503-511. (Pubitemid 47068069)
19. Rogalla P, Drechsler K, Schröder-Babo W, et al. HMGIC expression patterns in non-small lung cancer and surrounding tissue. Anticancer Res. 1998;18:3327-3330. (Pubitemid 28546455)
20. Hebert C, Norris K, Scheper MA, et al. High mobility group A2 is a target for miRNA-98 in head and neck squamous cell carcinoma. Mol Cancer. 2007;6:5.
21. Miyazawa J, Mitoro A, Kawashiri S, et al. Expression of mesenchyme-specific gene HMGA2 in squamous cell carcinomas of the oral cavity. Cancer Res. 2004;64:2024-2029. (Pubitemid 38339449)
22. Rogalla P, Drechsler K, Kazmierczak B, et al. Expression of HMGI-C, a member of the high mobility group protein family, in a subset of breast cancers: relationship to histologic grade. Mol Carcinog. 1997;19:153-156. (Pubitemid 27360132)
23. Fabjani G, Tong D, Wolf A, et al. HMGA2 is associated with invasiveness but not a suitable marker for the detection of circulating tumor cells in breast cancer. Oncol Rep. 2005;14:737-741.
24. Malek A, Bakhidze E, Noske A, et al. HMGA2 gene is a promising target for ovarian cancer silencing therapy. Int J Cancer. 2008; 123:348-356. (Pubitemid 351842019)
25. Franco R, Esposito F, Fedele M, et al. Detection of high-mobility group proteins A1 and A2 represents a valid diagnostic marker in post-pubertal testicular germ cell tumours. J Pathol. 2008;214:58-64.
26. Rahman M, Qian Z, Wang E, et al. Frequent overexpression of HMGA1 and 2 in gastroenteropancreatic neuroendocrine tumours and its relationship to let-7 downregulation. Br J Cancer. 2009; 100:501-510.
27. Prasad NB, Somervell H, Tufano RP, et al. Identification of genes differentially expressed in benign versus malignant thyroid tumors. Clin Cancer Res. 2008;14:3327-3337.
28. Belge G, Meyer A, Klemke M, et al. Upregulation of HMGA2 in thyroid carcinomas: a novel molecular marker to distinguish between benign and malignant follicular neoplasias. Genes Chromosomes Cancer. 2008;47:56-63. (Pubitemid 350191464)
29. Chiappetta G, Ferraro A, Vuttariello E, et al. HMGA2 mRNA expression correlates with the malignant phenotype in human thyroid neoplasias. Eur J Cancer. 2008;44:1015-1021.
30. Swartz K, Jin L, Erickson LA, et al. Real time quantitative RT-PCR analysis of high mobility group A2 (HMGA2) mRNA expression assists in distinguishing benign from malignant thyroid tumors. [abstract 1108]. Mod Pathol. 2009;21:242A.
31. Lappinga PJ, Kip NS, Jin L, et al. Use of HMGA2 overexpression by RT-PCR performed on suspicious cytology smears to preoperatively separate benign from malignant thyroid nodules. [abstract 431]. Mod Pathol. 2010;22:98A.
32. Jin L, Seys A, Zhang S, et al. Diagnostic utility of IMP3 expression in thyroid neoplasms: a quantitative RT-PCR study. Diagn Mol Pathol. 2010;19:63-69.
33. Baloch ZW, Fleisher S, LiVolsi VA, et al. Diagnosis of "follicular neoplasm": a gray zone in thyroid fine-needle aspiration cytology. Diagn Cytopathol. 2002;26:41-44. (Pubitemid 34037526)
34. Nikiforov YE, Steward DL, Robinson-Smith TM, et al. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab. 2009;94: 2092-2098.
35. Nikiforova MN, Nikiforov YE. Molecular diagnostics and predictors in thyroid cancer. Thyroid. 2009;19:1351-1361.
36. Nakamura N, Erickson LA, Jin L, et al. Immunohistochemical separation of follicular variant of papillary thyroid carcinoma from follicular adenoma. Endocr Pathol. 2006;17:213-223.
37. Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications (review). Endocr Rev. 2007;28:742-762. (Pubitemid 350294294)
38. Jin L, Sebo TJ, Nakamura N, et al. BRAF mutation analysis in fine needle aspiration (FNA) cytology of the thyroid. Diagn Mol Pathol. 2006;15:136-143. (Pubitemid 44325474)
39. Kroll TG, Sarraf P, Pecciarini L, et al. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. Science. 2000;289:1357-1360. (Pubitemid 30656054)
40. Sobrinho-Simões M, Preto A, Rocha AS, et al. Molecular pathology of well-differentiated thyroid carcinomas. Virchows Arch. 2005;447: 787-793. (Pubitemid 41728865)
41. Arora N, Scognamiglio T, Lubitz CC, et al. Identification of borderline thyroid tumors by gene expression array analysis. Cancer. 2009;115:5421-5431.